All In Biotech

Drug Trial Radar · NCT03781804

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

A 24-Week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Last checked: Nov 19, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

332

Actual

Start

Nov 27, 2018

Primary completion

Jan 19, 2022

Study completion Jan 19, 2022

Sponsor

Lead sponsor
Optinose US Inc.Industry
Sponsor type
Industry
First posted
Dec 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with chronic rhinosinusitis (CS) with or without nasal polyps.

Conditions

  • Chronic Rhinosinusitis

Interventions

  • OPN-375Drug

    OPN-375, BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior and/or Posterior) at the End of Week 4Time frame: 4 Weeks
  2. Change From Baseline to Week 24/Early Termination (ET) in the Average Percent of the Volume Opacified in the Ethmoid and Maxillary SinusesTime frame: Baseline, Week 24

Locations

92 sites in 8 countries. Site status is shown where the registry gives one.

  • AZ Allergy & Immunology Research

    Gilbert, Arizona

  • Kern Research

    Bakersfield, California

  • Sacramento Ear, Nose & Throat Surgical and Medical Group Inc

    Folsom, California

  • Allergy & Asthma Specialists Medical Group

    Huntington Beach, California

  • Jonathan Corren, MD, Clinical Research Division

    Los Angeles, California

  • Sacramento Ear, Nose & Throat

    Roseville, California

  • UC Davis Medical Center

    Sacramento, California

  • Allergy and Asthma Associates of Santa Clara Valley

    San Jose, California

  • Breathe Clear Institute

    Torrance, California

  • Allergy & Asthma Clinical Research

    Walnut Creek, California

  • Colorado ENT & Allergy

    Colorado Springs, Colorado

  • Yale School of Medicine Section of Otolaryngology

    New Haven, Connecticut

  • Emory University MOT

    Atlanta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • The University of Chicago

    Chicago, Illinois

  • Midwest Allergy Sinus Asthma

    Normal, Illinois

  • Advanced ENT and Allergy

    New Albany, Indiana

  • Iowa Head & Neck

    Des Moines, Iowa

  • Kentuckiana Ear Nose & Throat

    Louisville, Kentucky

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • John Hopkins Hospital

    Baltimore, Maryland

  • Ear, Nose and Throat Associates at Greater Baltimore Medical Center

    Towson, Maryland

  • St. Cloud Ear, Nose & Throat

    Saint Cloud, Minnesota

  • University of Missouri, Dept of Otorlaryngology

    Columbia, Missouri

  • Asthma, Allergy, and Immunology Associates, PC

    Lincoln, Nebraska

  • Atlantic Research Center

    Ocean City, New Jersey

  • ENT and Allergy Associates

    New Hyde Park, New York

  • Mount Sinai Downtown Union Square

    New York, New York

  • Madison ENT and Facial Plastic Surgery

    New York, New York

  • Allergy Asthma & Immunology Relief of Charlotte

    Charlotte, North Carolina

  • Allergy Asthma & Clinical Research Center

    Oklahoma City, Oklahoma

  • Vital Prospects Clinical Research Institute, P.C.

    Tulsa, Oklahoma

  • Northwest Research Center

    Portland, Oregon

  • Specialty Physician Associates

    Bethlehem, Pennsylvania

  • Hospital at the University of PA

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • National Allergy and Asthma Research

    North Charleston, South Carolina

  • Holston Medical Group

    Kingsport, Tennessee

  • University of TX Health Science Ctr at Houston

    Houston, Texas

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.